Larimar Therapeutics
repeated subcutaneous injections of were generally well tolerated in phase mad trial | Larimar Therapeutics
Company
Deck Type
Sector
Industry
Deck date
November 2023
Slide
30 of 44
Similar slides by Larimar Therapeutics
See diffirences between slides (animation)
Investor Presentation
November 2023
appeared to be generally well tolerated in phase trial cohort | Larimar Therapeutics
Investor Presentation
November 2023
data is generally well tolerated | Larimar Therapeutics
Related slides by other companies
AN2 Therapeutics
Investor Presentation
February 2025
next unblind phase data | AN2 Therapeutics
AN2 Therapeutics
Investor Presentation
March 2025
next unblind phase data | AN2 Therapeutics
RenovoRx
IPO
August 2021
designed for success one phase trial to approval pivotal tiger pac phase study schema currently enrolling | RenovoRx
MAIA Biotechnology
Investor Presentation
November 2023
thio trial planned a | MAIA Biotechnology
Other recent decks by Larimar Therapeutics
See all presentations (3 decks)
Results
November 2022
Investor Presentation
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights